Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01751516 · ClinicalTrials.gov registry record

PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study

A clinical trial of Rectal Carcinoma, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
8
Enrollment target
1
Study location

NCT01751516 is a study of Rectal Carcinoma that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 8 participants, below the 31,043-participant average among 5 other Rectal Carcinoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01751516, a study of Rectal Carcinoma, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
8 participants
Enrollment target
1
Study location

Study Summary

This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.

Conditions Studied

Study Locations (1)

North Carolina

  • University of North Carolina-Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2012-10
Est. Completion 2018-03-04

What the Registry Record Tells You About NCT01751516

The ClinicalTrials.gov registry entry for NCT01751516 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 31,043-participant average among 5 other Rectal Carcinoma trials with a reported enrollment target (100% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rectal Carcinoma appearing as the primary indexed condition, and to 0 interventions.

NCT01751516 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT01751516 about?

NCT01751516 is a clinical study titled "PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study". This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.

What is the current status of trial NCT01751516?

This trial is currently completed. The enrollment target is 8 participants. The study started on 2012-10. Estimated completion is 2018-03-04.

What conditions does trial NCT01751516 study?

This clinical trial studies the following conditions: Rectal Carcinoma.

Who is sponsoring clinical trial NCT01751516?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01751516 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rectal Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.